Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS -- Tokens.com Reports 2021 Financial Results
TORONTO, April 04, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN)(Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse, Defi, Blockchain Gaming and NFTs, is pleased to report its financial results for the 12 months ending December 30, 2021.
"Q4 was our third quarter as a public company and our second full quarter with the proceeds from the April 2021 fundraise deployed," said Andrew Kiguel, CEO of Tokens.com. "We achieved several milestones in 2021, including going public and two capital raises. We diversified our investments into new Web3 verticals including blockchain gaming and building a significant business in the Metaverse sector."
All dollar figures are in United States dollars ("USD"), unless otherwise stated.
2021 Operational Highlights:
NEWS -- Tokens.com Announces Time Change for 2021 Audited Financial Results Investor Call
TORONTO, April 01, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse, Defi, Gaming and NFTs, announces a change in time for its investor call to discuss its 2021 audited financial results.
The call is being rescheduled from 10:00 am ET on Friday April 1st to 4:00 pm ET on Monday April 4th, 2022.
Updated Conference Call Details:
Date: April 4, 2022
Time: 4:00 p.m. ET
Dial-In: 1 (866)455-3403
Passcode: 57798376#
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns and invests in an inventory of Metaverse, NFT, DeFi, and gaming based digital assets. Tokens.com’s focus is to invest in and build Web3 businesses through its primary entity and subsidiaries. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220401005118/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
+1-647-578-7490
mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
mailto://contact@tokens.com
Media: Ali Clarke – Talk Shop Media
mailto://ali@talkshopmedia.com
NEWS -- Tokens.com Announces Time Change for 2021 Audited Financial Results Investor Call
TORONTO, April 01, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse, Defi, Gaming and NFTs, announces a change in time for its investor call to discuss its 2021 audited financial results.
The call is being rescheduled from 10:00 am ET on Friday April 1st to 4:00 pm ET on Monday April 4th, 2022.
Updated Conference Call Details:
Date: April 4, 2022
Time: 4:00 p.m. ET
Dial-In: 1 (866)455-3403
Passcode: 57798376#
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns and invests in an inventory of Metaverse, NFT, DeFi, and gaming based digital assets. Tokens.com’s focus is to invest in and build Web3 businesses through its primary entity and subsidiaries. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220401005118/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
+1-647-578-7490
mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
mailto://contact@tokens.com
Media: Ali Clarke – Talk Shop Media
mailto://ali@talkshopmedia.com
Direct link to Ian Clifford's talk The Business Groth Pod:
http://allandraper.com/s2ep65-build-a-successful-company-culture-with-shared-goals-and-values/
NEWS -- IBN (InvestorBrandNetwork) Announces The Business Growth Pod Interview with FuelPositive Corp. CEO Ian Clifford
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company for private and public entities, today announces that Ian Clifford, Director, CEO and Founder of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), recently appeared on The Business Growth Pod, a podcast series designed specifically to help those wanting to start and grow a business. FuelPositive is a technology company focused on providing commercially viable and sustainable solutions, including green ammonia, to reduce carbon emissions and combat climate change. By focusing on technologies that are clean, economical and build easily on what is already in place, FuelPositive will affect the course of climate change through practical solutions that can be implemented in the short term.
The broadcast, hosted by serial entrepreneur and business expert Allan Draper, is available for on-demand listening on The Business Growth Pod.
During the interview, Clifford discussed the history of FuelPositive before turning his attention to his philosophies for hiring and building a team.
“The genesis of FuelPositive happened about 18 months ago, coming out of an energy storage technology that we’re commercializing. We became really interested in replacements for fossil fuel,” Clifford said. “We started looking at green ammonia. When people think of ammonia, they think of cleaning products or a skating rink that has a weird smell. In our research, we learned that ammonia is an incredibly versatile molecule, and there are ways of producing it that are absolutely carbon free. It is a material that can be produced in a pure, green way that can then be utilized in agriculture as a fertilizer, as a fossil fuel replacement running an internal combustion engine or as a great refrigerant.”
“We became really compelled with this and did extensive due diligence on the technology and the inventors who were developing it,” he continued. “Last April, we entered into an agreement to purchase the intellectual property for the purposes of commercializing it, which is what we’re doing right now. … This is through a number of different startup phases looking at different technologies in the past. … I’ve been through many, many startups and a number of exits, and I’m really excited about the team that we have put together with FuelPositive.”
“I think the biggest challenge for any entrepreneur is to find the right people. I start by making sure that the values and the mission of the company are very clearly stated, so you’re really transparent in terms of your goals and your values,” Clifford added. “Then, I typically start people or groups on a contract basis. … It gives you a really good impression of how they treat you when you’re the ‘customer.’ You get a really good sense of how seriously they take the relationship with you, how they manage their time, how they bill you and all of those really important intrinsic aspects of those relationships. … I like to test the waters slowly.”
Throughout the interview, Clifford continued to discuss his leadership approach and the business philosophies guiding the growth and development of FuelPositive.
Learn more by listening to the full interview on The Business Growth Pod.
About FuelPositive Corp.
FuelPositive Corp. is a Canadian growth-stage technology company committed to providing commercially viable and sustainable “cradle to cradle” clean technology solutions, including green ammonia (NH3), for use across a broad spectrum of industries and applications. By focusing on technologies that are clean and economically advantageous/realizable, the company aims to change the course of climate change through practical solutions that can be implemented now. The company’s core technology, a modular and scalable green ammonia production system, takes air, water and sustainable electricity and synthesizes it into a non-polluting chemical for multiple applications, including fertilizer for farming, fuel for internal combustion engines and a solution for grid storage. Green ammonia is being considered as a replacement for fossil fuels and as a key enabler of the hydrogen economy. For more information, visit the company’s website at https://www.FuelPositive.com.
About IBN
IBN (InvestorBrandNetwork) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.
For more information, please visit https://www.InvestorBrandNetwork.com.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN wherever published or re-published: http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
https://www.InvestorBrandNetwork.com
310.299.1717 Office
mailto://Editor@InvestorBrandNetwork.com
NEWS -- Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
Independent review identified, no safety concerns in trial's final safety run-in
Cohort supported by prior clinical data showing a pelareorep-based combination driving a 90% clinical benefit rate in KRAS-mutated colorectal cancer patients
Multi-indication trial being conducted in collaboration with Roche and AIO also includes pancreatic and advanced anal cancer cohorts
SAN DIEGO, Calif. and CALGARY, AB, March 31, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the successful completion of the three-patient safety run-in for the third-line metastatic colorectal cancer (mCRC) cohort of the phase 1/2 GOBLET study, following an independent review by the study's Data Safety Monitoring Board (DSMB). The DSMB noted no safety concerns in these patients and has recommended that the study proceed to full enrollment pending clearance by the Paul Ehrlich Institute (PEI; Germany's medical regulatory body). The PEI recently cleared the study's pancreatic cancer cohort for full enrollment following a similar recommendation by the DSMB. The trial's anal cancer and first-line mCRC cohorts do not include safety run-ins and are proceeding as planned.
The GOBLET study is designed to evaluate the safety and efficacy of pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab in patients with metastatic pancreatic, metastatic colorectal, and advanced anal cancers. The study includes 14 clinical trial sites across Germany and is being managed by AIO, a leading academic cooperative medical oncology group.
"The successful completion of GOBLET's final safety run-in underscores the trial's strong momentum and supports the ability of pelareorep to be safely combined with checkpoint inhibitors," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer of Oncolytics. "This achievement positions us to continue building on prior clinical data that demonstrate the potential of pelareorep to provide a clinical benefit in colorectal and other gastrointestinal (GI) cancers. Existing data suggest this clinical benefit likely results from the stimulation of protective immune responses that may be enhanced by the addition of checkpoint inhibition. Given the high prevalence of GI malignancies, including colorectal and pancreatic cancer, and the fact that most cases do not respond to checkpoint inhibition, we view GOBLET as an important opportunity to evaluate a novel therapeutic approach that may address a pressing unmet medical need."
The GOBLET study's metastatic colorectal cancer cohorts are supported by prior clinical data demonstrating adaptive anti-tumor immune responses and a 90% clinical benefit rate in KRAS-mutated mCRC patients treated with a pelareorep-based combination (link to PR, link to study). In addition to primary endpoints evaluating safety and efficacy, GOBLET also includes exploratory endpoints designed to explore the potential of CEACAM6 and T cell clonality to serve as predictive biomarkers. This may increase the likelihood of success of future registrational studies by allowing for the selection of the most appropriate patients.
About GOBLET
The GOBLET (Gastrointestinal tumors exploring the treatment combinations with the oncolytic reovirus pelareorep and anti-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 14 centers in Germany. The co-primary endpoints of the study are objective response rate (ORR) assessed at week 16 and safety. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers (T cell clonality and CEACAM6). The study employs a Simon two-stage design with Stage 1 comprising four treatment groups expected to enroll a total of approximately 55 patients:
1. Pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1st line metastatic pancreatic cancer patients (n=12);
2. Pelareorep in combination with atezolizumab in 1st line MSI (microsatellite instability)-high metastatic colorectal cancer patients (n=19);
3. Pelareorep in combination with atezolizumab and TAS-102 in 3rd line metastatic colorectal cancer patients (n=14); and
4. Pelareorep in combination with atezolizumab in 2nd line advanced and unresectable anal cancer patients (n=10).
Any cohort showing an ORR above a pre-specified threshold in Stage 1 may be advanced to Stage 2 and enroll additional patients.
About AIO
AIO-Studien-gGmbH (AIO) emerged from the study center of the internal oncology working group within the German Cancer Society (DKG). AIO operates with a non-profit purpose of promoting science and research with a focus on internal oncology. Since its foundation, AIO has become a successful sponsor and study management company and has established itself both nationally and internationally.
About Gastrointestinal Cancer
Excluding skin cancers, colorectal cancer is the third most common cancer, with estimates indicating that 106,180 new cases of colon cancer and 44,850 new cases of rectal cancer will be diagnosed in the U.S. in 20221. Also, for the 2022 year, the American Cancer Society estimates there will be 62,210 new cases of pancreatic cancer2 and 9,440 new cases of anal cancer3 in the U.S.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: https://www.oncolyticsbiotech.com.
References
1. "Key Statistics for Colorectal Cancer." The American Cancer Society, American Cancer Society, Inc., https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html
3. "Key Statistics for Pancreatic Cancer." The American Cancer Society, American Cancer Society, Inc., https://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html
3. "Key Statistics for Anal Cancer." The American Cancer Society, American Cancer Society, Inc., https://www.cancer.org/cancer/anal-cancer/about/what-is-key-statistics.html
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; management's expectations as to enrollment in the company's GOBLET study, our beliefs regarding the potential of CEACAM6 and T cell clonality to predict patient responses to therapy and improvements to our ability to select patients most likely to respond to pelareorep-based therapies in future trials across multiple indications; our plans to advance towards a registration study in metastatic breast cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Company Contact
Jon Patton
Director of IR & Communication
+1-858-886-7813
mailto://jpatton@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
mailto://tim@lifesciadvisors.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/oncolytics-biotech-provides-positive-safety-update-on-the-third-line-metastatic-colorectal-cancer-cohort-of-its-multi-indication-phase-12-gastrointestinal-cancer-trial-301514611.html
SOURCE Oncolytics Biotech® Inc.
NEWS -- Nanomix Appoints Vidur Sahney as Chief Operating Officer
Relocates Headquarters and Labs to a Larger Facility while Reducing Overhead Expense
SAN LEANDRO, Calif., March 30, 2022--(BUSINESS WIRE)--Nanomix Corporation (OTCBB: NNMX, NNMXD), a leader in the development of mobile, affordable, point-of-care diagnostics, announces the appointment of Vidur Sahney as Chief Operating Officer. Mr. Sahney brings to Nanomix more than 20 years of experience in operations, quality, validation, manufacturing and research. In this newly created executive management position, Mr. Sahney will manage and be responsible for Nanomix operations including manufacturing, assay development and quality.
Additionally, Nanomix announces the relocation of its corporate headquarters and laboratories to a 9,325 square foot facility at 2121 Williams Street, San Leandro, California 94577. The new location is approximately 50% larger and half the cost of the previous site. All Nanomix telephone numbers, email and website addresses are unchanged.
"Vidur is an accomplished operational executive and I am proud to welcome him to the Nanomix management team. His experience in establishing world-class manufacturing operations, including particular strengths in healthcare devices and cartridge-device systems, is a great fit and will be critical to our growth as a leader in point-of-care diagnostics," stated David Ludvigson, President and Chief Executive Officer of Nanomix. "Our move to a larger, cost efficient location and the addition of Vidur to our management team are both key components of our transition to commercial activities."
"I am excited to join Nanomix as we build up our capabilities and begin to expand our menu of tests. Mobile point-of-care diagnostics are increasingly in demand – in particular where time and accuracy are critical for clinical decision-making and patient care. I look forward to leveraging my experience to accelerate the growth of the Nanomix eLab system to leverage this need," added Mr. Sahney.
Most recently, Mr. Sahney served as Chief Operating Officer of ExThera Medical where he led the initiative to secure U.S. Food and Drug Administration (FDA) Emergency Use Authorization site clearance and CE mark for a Class III / PMA medical device, and commercialized the novel hemoperfusion filter used to treat blood stream infections and COVID-19 in Europe and the U.S. Prior to that, Mr. Sahney worked at JUUL Labs where he oversaw global operations, including supply chain and technical operations, and the manufacturing of devices and pods.
Prior to JUUL, Mr. Sahney served in various healthcare companies where he established commercial footprints and secured FDA clearances. He served as Vice President of Operations at Sientra, where he led the initiative for FDA site clearance for a Class III / PMA medical device. At Thoratec he was responsible for commercializing the Class III / PMA HeartMate Percutaneous Heart Pump program, which later led to the company’s acquisition by St. Jude Medical. Mr. Sahney also served as Senior Director of Manufacturing and Operations at CR Bard Vascular / Loma Vista Medical (by acquisition), where he led the operations and development of a novel fiber composite balloon catheter from conception to commercialization and worked at Abbott Vascular and Abbott Diabetes Care in manufacturing and process engineering positions.
Mr. Sahney received a Bachelor of Science in Mechanical Engineering from San Francisco State University.
About Nanomix Corporation
Nanomix is the leader in the development of mobile point-of-care diagnostics with its Nanomix eLab platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, with the goal to enable faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assay addresses the critical need for faster diagnosis of critical infections. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes. For more information, visit https://www.nano.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220330005145/en/
Contacts
LHA Investor Relations
Tirth T. Patel
212-201-6614
mailto://tpatel@lhai.com
NEWS -- FuelPositive Announces Key Market Research Appointments
Fully understanding the customer’s reality will guide decision-making as FuelPositive prepares for commercialization
TORONTO, March 29, 2022 (GLOBE NEWSWIRE) -- FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) (“FuelPositive” or the “Company”) is pleased to announce two key appointments focused on fully understanding its customers as it nears market entry. Pollara Strategic Insights has been appointed FuelPositive’s market research partner. As well, Leith Deacon, an Associate Professor and researcher from the University of Guelph, has been appointed as an Advisor, helping to guide the Company’s market research efforts.
“We have identified the farming community in Canada as our first customer for our on-site green ammonia production system. That means we need to learn everything we can about farmers. We already know they are a diverse group. We need to understand how the farmers who will be attracted to our product think and what they need in order to succeed. We’ve decided to take the same disciplined approach to our market research that our R&D and Operations teams take to their work – one that is based on evidence and the scientific method. Involving Pollara and Dr. Deacon in our market research will ensure we develop the most useful and environmentally positive product and that we support our customers in farming in the most sustainable way possible,” said Ian Clifford, FuelPositive Board Chair and CEO.
FuelPositive’s core technology is a scalable, containerized “plant-in-a-box” that uses a carbon-free process to make pure ammonia which is used on farms as fertilizer. Already proven in the lab, the Company is currently building full-sized demonstration systems to validate its technology. The first system is scheduled to be launched on a farm in Manitoba, Canada, in late summer 2022, followed by two additional demonstration systems later. Eighty per cent of the current global supply of ammonia is used as fertilizer by the agriculture sector.
“This market research will guide us as we determine a definitive revenue model for our product. We are considering a number of options. We can sell the units, we can lease, we can own and charge per operational hour, or we can rent to own. What model is the best one for farmers? The research – informed by farmers themselves – will help us gain the insights we need before we begin to take orders. It will also help us make informed decisions as we continually improve the systems we are building,” added Clifford.
“We are excited by FuelPositive’s approach to making farming more sustainable. Our team has extensive experience in the agriculture space, especially in terms of sustainable and regenerative farming. We are conducting qualitative interviews and quantitative surveys across a robust sample of Canadian farmers to extract deep insights and direction for the Company to consider when making its decisions,” said Don Guy, Pollara Strategic Insights.
“I am pleased that my background in rural planning and development will be useful for FuelPositive. I’m a firm believer in data-based decision-making. It’s important to recognize that if you’re designing a product for farmers, you need to make sure the product is reflective of farmers’ realities. The only way to know what they need and want is to ask them. I’m excited to see that FuelPositive is engaging directly with farmers and taking its decision-making so seriously,” said Dr. Deacon.
About Pollara Strategic Insights
Founded in 1980, Pollara Strategic Insights is one of Canada’s premier full-service research firms – a collaborative team of senior research veterans who are passionate about conducting research through hands-on creativity and customized solutions. Taking full advantage of their comprehensive toolbox of industry-leading quantitative and qualitative methodologies and analytical techniques, Pollara provides research-based strategic advice to a wide array of clients across all sectors on a local, national and global scale. For more information, please visit https://www.pollara.com.
About Leith Deacon
Leith Deacon, BA, MSc and PhD, is an Associate Professor in the Rural Planning and Development Program in the School of Environmental Design and Rural Development at the University of Guelph. He is a full member of the Canadian Institute of Planners and a Registered Professional Planner. Leith’s research focuses on rural and small communities and concepts around sustainability, governance and resiliency. Leith uses mixed methodologies to gather local data that can inform local policy and program decisions. A recent research project resulted in a data-based of 30,000 individuals living in rural Ontario.
About FuelPositive
FuelPositive is a Canadian technology company committed to providing commercially viable and sustainable “cradle to cradle” clean technology solutions, including green ammonia (NH3), for use across a broad spectrum of industries and applications. By focusing on technologies that are clean, sustainable and economically advantageous/realizable, the Company aims to change the course of climate change through practical solutions that can be implemented now.
The FuelPositive green ammonia system takes air, water and sustainable electricity and synthesizes it into pure, anhydrous ammonia for multiple applications, including fertilizer for farming, fuel for grain drying and internal combustion engines and a solution for grid storage. Green ammonia is also being considered as a key enabler of the hydrogen economy.
FuelPositive systems are designed to provide for green ammonia production on-site, where it’s needed. This eliminates wildly fluctuating supply chains and offers end-user energy and supply security.
Cautionary Statement
Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) that are based on expectations, estimates and projections as at the date of this news release. The information in this release about future plans and objectives of the Company, including the expected expenditures of the proceeds of the private placement, are forward-looking statements.
These forward-looking statements are based on assumptions and estimates of management of the Company at the time they were made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect.
Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Forward-looking information is provided for the purpose of providing information about management’s expectations and plans relating to the future. The Company disclaims any intention or obligation to update or revise any forward-looking information or to explain any material difference between subsequent actual events and such forward-looking information, except to the extent required by applicable law.
For Media or Investor enquiries, please contact:
Ian Clifford
Chief Executive Officer and Board Chair
mailto://mailbox1@fuelpositive.com
https://www.fuelpositive.com
Investor Relations (United States)
RBMG – RB Milestone Group LLC
Trevor Brucato, Managing Director
mailto://fuelpositive@rbmilestone.com
https://www.rbmilestone.com
NEWS -- Tokens.com Launches Canada SailGP Team Metaverse Headquarters
TORONTO, March 29, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to share that its subsidiary, Metaverse Group, has signed a lease agreement with Canada SailGP Team for its Metaverse headquarters. Tokens.com portfolio company, Metaverse Architects, has provided the design and architecture services for the installation, which is now live in Decentraland.
Canada SailGP Team is the newest team in the ultra-competitive SailGP circuit - the world’s most exciting race on-water with national teams battling in short, intense races at iconic stadium-style venues across the globe, building to the grand final – and a top prize of US$1 million. The high-tech, high-speed racing features sailing’s best athletes competing in identical hydro foiling F50 catamarans, flying at speeds approaching 100 km/h.
"I am very excited for this collaboration," said Fred Pye, owner of Canada SailGP Team. "SailGP is at the cutting edge of its domain in a similar way to how Tokens.com and Metaverse Group each are dedicated to pushing what’s possible in their own realms. Our collaboration is aimed at helping form the new standards of how physical world firms engage in this new digital frontier and I look forward to what we will do next."
The headquarters consists of two structures, which include the Canada SailGP Team head office. The team has commissioned Metaverse Architects to develop a display of live streams of Canada SailGP Team’s leading edge technology and create the Canada SailGP Team NFT collection. The headquarters is situated on the equivalent of 60,000 square feet of flat land. Visitors will be able to explore structures, get information on future races and spend time in dedicated meeting rooms that will showcase the Canadian team racing.
"Canada SailGP Team’s Metaverse presence bridges the gap between the physical and virtual world," commented Andrew Kiguel, Tokens.com CEO and Executive Chairman of Metaverse Group. "We are proud to have them as a tenant and provide them with design development on our property. Metaverse Group is a one-stop shop for brands seeking to enter this new realm. We are excited to launch Canada SailGP Team’s presence in the Metaverse and showcase the team to a new audience. We look forward to cheering on the Canada SailGP Team in their races."
These headquarters give fans an opportunity to get closer to the sport and experience all it has to offer in a way that was not previously possible. With the team strategically located in Decentraland, it will further bring new awareness to the team and sport.
Brands or virtual landowners interested in partnering with Metaverse Group should contact mailto://Info@metaversegroup.com.
Brands seeking design and architecture services should contact mailto://Osher@mvarchitects.io
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns and invests in an inventory of Metaverse, NFT, DeFi, and gaming based digital assets. Tokens.com’s focus is to invest in and build Web3 businesses through its primary entity and subsidiaries. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3. Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s CryptoValley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly-traded company, is the majority owner of Metaverse Group. For further information please visit https://metaversegroup.com.
Canada SailGP Team
Canada SailGP Team is an independently-owned professional sailing team competing in SailGP. The team and its partners are committed to inspiring the next generation of sailors across Canada and establishing a pathway for extraordinary athletes in the sport. The Canadian team is an entrepreneurial start up that is all about passion, purpose and risk-taking – elements that lead to winning. For further information visit https://sailgp.com/teams/canada
About Metaverse Architects
Metaverse Architects is a fully fledged architecture studio, specializing in the cutting edge of virtual spaces. Hailing from the traditional architectural discipline, Metaverse Architects’ aim is to lead the advancement of Metaverse as a Web3 frontier, pushing the envelope of design, functionality and experience. The firm specializes in a multitude of Metaverse instances, as well as NFTs and digital art. For more information, please contact:
Osher Frank, Chief Architect
mailto://Osher@mvarchitects.io
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005195/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com Launches Canada SailGP Team Metaverse Headquarters
TORONTO, March 29, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to share that its subsidiary, Metaverse Group, has signed a lease agreement with Canada SailGP Team for its Metaverse headquarters. Tokens.com portfolio company, Metaverse Architects, has provided the design and architecture services for the installation, which is now live in Decentraland.
Canada SailGP Team is the newest team in the ultra-competitive SailGP circuit - the world’s most exciting race on-water with national teams battling in short, intense races at iconic stadium-style venues across the globe, building to the grand final – and a top prize of US$1 million. The high-tech, high-speed racing features sailing’s best athletes competing in identical hydro foiling F50 catamarans, flying at speeds approaching 100 km/h.
"I am very excited for this collaboration," said Fred Pye, owner of Canada SailGP Team. "SailGP is at the cutting edge of its domain in a similar way to how Tokens.com and Metaverse Group each are dedicated to pushing what’s possible in their own realms. Our collaboration is aimed at helping form the new standards of how physical world firms engage in this new digital frontier and I look forward to what we will do next."
The headquarters consists of two structures, which include the Canada SailGP Team head office. The team has commissioned Metaverse Architects to develop a display of live streams of Canada SailGP Team’s leading edge technology and create the Canada SailGP Team NFT collection. The headquarters is situated on the equivalent of 60,000 square feet of flat land. Visitors will be able to explore structures, get information on future races and spend time in dedicated meeting rooms that will showcase the Canadian team racing.
"Canada SailGP Team’s Metaverse presence bridges the gap between the physical and virtual world," commented Andrew Kiguel, Tokens.com CEO and Executive Chairman of Metaverse Group. "We are proud to have them as a tenant and provide them with design development on our property. Metaverse Group is a one-stop shop for brands seeking to enter this new realm. We are excited to launch Canada SailGP Team’s presence in the Metaverse and showcase the team to a new audience. We look forward to cheering on the Canada SailGP Team in their races."
These headquarters give fans an opportunity to get closer to the sport and experience all it has to offer in a way that was not previously possible. With the team strategically located in Decentraland, it will further bring new awareness to the team and sport.
Brands or virtual landowners interested in partnering with Metaverse Group should contact mailto://Info@metaversegroup.com.
Brands seeking design and architecture services should contact mailto://Osher@mvarchitects.io
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns and invests in an inventory of Metaverse, NFT, DeFi, and gaming based digital assets. Tokens.com’s focus is to invest in and build Web3 businesses through its primary entity and subsidiaries. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3. Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s CryptoValley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly-traded company, is the majority owner of Metaverse Group. For further information please visit https://metaversegroup.com.
Canada SailGP Team
Canada SailGP Team is an independently-owned professional sailing team competing in SailGP. The team and its partners are committed to inspiring the next generation of sailors across Canada and establishing a pathway for extraordinary athletes in the sport. The Canadian team is an entrepreneurial start up that is all about passion, purpose and risk-taking – elements that lead to winning. For further information visit https://sailgp.com/teams/canada
About Metaverse Architects
Metaverse Architects is a fully fledged architecture studio, specializing in the cutting edge of virtual spaces. Hailing from the traditional architectural discipline, Metaverse Architects’ aim is to lead the advancement of Metaverse as a Web3 frontier, pushing the envelope of design, functionality and experience. The firm specializes in a multitude of Metaverse instances, as well as NFTs and digital art. For more information, please contact:
Osher Frank, Chief Architect
mailto://Osher@mvarchitects.io
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005195/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process
NEWS -- Nanomix Corporation Announces Securities Purchase Agreement With GHS Investments for up to $3.0 Million
EMERYVILLE, Calif., March 25, 2022--(BUSINESS WIRE)--Nanomix Corporation (OTCBB: NNMX, NNMXD), a leader in the development of mobile, affordable, point-of-care diagnostics, announces it has entered into a $3.0 million securities purchase agreement with GHS Investments, LLC (GHS), a leading private investment and management group.
"This agreement is an important step in the transition of our business from development stage to commercial operations. GHS has an impressive track record of investing in small-cap companies with a promising outlook, and we believe they will be a valuable partner to Nanomix," stated David Ludvigson, President and Chief Executive Officer of Nanomix.
Under the terms of the securities purchase agreement, Nanomix will have the right to sell up to $3.0 million of common stock to GHS across multiple tranches over the next several months. For more information on the agreement, please refer to the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange and available at https://www.sec.gov.
About Nanomix Corporation
Nanomix is the leader in the development of mobile point-of-care diagnostics with its Nanomix eLab platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, with the goal to enable faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assay addresses the critical need for faster diagnosis of critical infections. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes. For more information, visit https://www.nano.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220325005085/en/
Contacts
LHA Investor Relations
Tirth Patel
212-201-6614
mailto://tpatel@lhai.com
NEWS -- Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022
CARLSBAD, Calif., March 24, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, the Company’s Chief Executive Officer, will be presenting at the 022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest. Mr. Culley will be participating in an "Ophthalmology Panel" hosted by Jason McCarthy, Ph.D., Senior Managing Director, Biotechnology, on March 28th, 2022 at 10am ET / 7am PT. Mr. Culley will also provide a corporate overview which will be available to investors on demand, starting on Monday March 28th, 2022.
The live panel and on-demand presentation will be available to registered users directly through the M-Vest platform: https://m-vest.com/events/2022-virtual-growth-conference. Registration is required for conference participation. An archived webcast of the corporate presentation will also be available on the Events and Presentations page of the Lineage website. Additional videos are available on the Media page of the Lineage website.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include four allogeneic ("off-the-shelf") product candidates: (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer and (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy. For more information, please visit https://www.lineagecell.com or follow the Company on Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005234/en/
Contacts
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(mailto://ir@lineagecell.com)
(442) 287-8963
Solebury Trout IR
Mike Biega
(mailto://Mbiega@soleburytrout.com)
(617) 221-9660
Russo Partners – Media Relations
Nic Johnson or David Schull
mailto://Nic.johnson@russopartnersllc.com
mailto://David.schull@russopartnersllc.com
(212) 845-4242
NEWS -- Tokens.com Partners with Forever 21 for Metaverse Storefront
TORONTO, March 24, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to share that its subsidiary, Metaverse Group, has signed a lease agreement for its Metaverse based property with Forever 21. In addition, Metaverse Group will collaborate with Forever 21 to design and build NFT wearables and an immersive storefront.
Forever 21 will open the doors to its Metaverse storefront in Decentraland’s Fashion District during Metaverse Fashion Week, which takes place from March 24th to March 27th. The dynamic storefront will feature avatars that will act as Forever 21 sales team members, ambient sounds and custom fixtures throughout. The shop will launch with ten Forever 21 NFT fashion items, inspired by pieces that are available in Forever 21’s physical stores and on forever21.com.
"Our estate in the Fashion District is evolving into one of the key shopping destinations in the Metaverse. Forever 21 is a fashion industry authority and represents a significant partner in enhancing the user experience and in helping us achieve this goal," commented Andrew Kiguel, CEO of Tokens.com and Executive Chair of Metaverse Group. "The momentum we are generating through these kinds of partnerships is evidence that the Metaverse and Web3 are changing how we use the internet and shop online."
This partnership was created by Tokens.com and Authentic Brands Group (ABG), a global brand development, marketing and entertainment company, and the owner of the Forever 21 brand.
Winnie Park, CEO of Forever 21 added, "When Forever 21 first entered the Metaverse, we were able to harness a unique opportunity to connect with a growing audience. Being a part of the first-ever Metaverse Fashion Week aligns with our mission to encourage self-expression through virtual and physical fashion. We are proud to partner with Metaverse Group as an avenue to connect our brand with a new demographic."
The Fashion Estate owned by Metaverse Group, where Forever 21 will open its virtual storefront, represents the equivalent of 450,000 sq ft of real estate that can be developed to any brand’s specifications. The Fashion District has finite space available, and storefronts are leased to premium brands and retailers. Brands or virtual landowners interested in partnering with Metaverse Group should contact mailto://info@metaversegroup.com.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in Web3 assets and businesses focused on the Metaverse, NFTs, DeFi, and gaming based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight-figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly-traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
About Forever 21
Forever 21 is a fashion industry leader making latest trends accessible to all while inspiring unique style and confidence. With a renewed focus on the customer experience, the brand offers high style designs and fashion basics with compelling values and a dynamic store environment. While driving innovation across e-commerce and digital to expand access and convenience, the brand continues to strengthen its positioning as today’s preferred destination for the fashionable consumer. Forever 21 is located in more than 540 locations globally and online. For more information visit https://Forever21.com.
Visit: https://forever21.com.
Follow @forever21 on Instagram, Facebook and Twitter.
About Authentic Brands Group
Authentic Brands Group (ABG) is a brand development, marketing and entertainment company, which owns a portfolio of global media, entertainment and lifestyle brands. Headquartered in New York City, ABG elevates and builds the long-term value of more than 50 consumer brands and properties by partnering with best-in-class manufacturers, wholesalers and retailers. Its brands have a global retail footprint across the luxury, specialty, department store, mid-tier, mass and e-commerce channels and in more than 7,500 freestanding stores and shop-in-shops around the world.
ABG is committed to transforming brands by delivering compelling product, content, business and immersive experiences. It creates and activates original marketing strategies to drive the success of its brands across all consumer touchpoints, platforms and emerging media. ABG’s portfolio of iconic and world-renowned brands includes Marilyn Monroe®, Elvis Presley®, Muhammad Ali®, Shaquille O'Neal®, David Beckham®, Dr. J®, Greg Norman®, Neil Lane®, Thalia®, Sports Illustrated®, Reebok®, Eddie Bauer®, Spyder®, Volcom®, Airwalk®, Nautica®, Izod®, Forever 21®, Aéropostale®, Juicy Couture®, Vince Camuto®, Lucky Brand®, Nine West®, Jones New York®, Frederick's of Hollywood®, Adrienne Vittadini®, Van Heusen®, Arrow®, Tretorn®, Tapout®, Prince®, Vision Street Wear®, Brooks Brothers®, Barneys New York®, Judith Leiber®, Herve Leger®, Frye®, Hickey Freeman®, Hart Schaffner Marx®, Thomasville®, Drexel® and Henredon®.
For more information, visit https://authenticbrands.com.
Follow ABG on Twitter, LinkedIn and Instagram.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005260/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email:mailto:// contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
Giana Elenterio, Director of Public Relations
mailto://gelenterio@authenticbrands.com
NEWS -- Tokens.com Partners with Forever 21 for Metaverse Storefront
TORONTO, March 24, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to share that its subsidiary, Metaverse Group, has signed a lease agreement for its Metaverse based property with Forever 21. In addition, Metaverse Group will collaborate with Forever 21 to design and build NFT wearables and an immersive storefront.
Forever 21 will open the doors to its Metaverse storefront in Decentraland’s Fashion District during Metaverse Fashion Week, which takes place from March 24th to March 27th. The dynamic storefront will feature avatars that will act as Forever 21 sales team members, ambient sounds and custom fixtures throughout. The shop will launch with ten Forever 21 NFT fashion items, inspired by pieces that are available in Forever 21’s physical stores and on forever21.com.
"Our estate in the Fashion District is evolving into one of the key shopping destinations in the Metaverse. Forever 21 is a fashion industry authority and represents a significant partner in enhancing the user experience and in helping us achieve this goal," commented Andrew Kiguel, CEO of Tokens.com and Executive Chair of Metaverse Group. "The momentum we are generating through these kinds of partnerships is evidence that the Metaverse and Web3 are changing how we use the internet and shop online."
This partnership was created by Tokens.com and Authentic Brands Group (ABG), a global brand development, marketing and entertainment company, and the owner of the Forever 21 brand.
Winnie Park, CEO of Forever 21 added, "When Forever 21 first entered the Metaverse, we were able to harness a unique opportunity to connect with a growing audience. Being a part of the first-ever Metaverse Fashion Week aligns with our mission to encourage self-expression through virtual and physical fashion. We are proud to partner with Metaverse Group as an avenue to connect our brand with a new demographic."
The Fashion Estate owned by Metaverse Group, where Forever 21 will open its virtual storefront, represents the equivalent of 450,000 sq ft of real estate that can be developed to any brand’s specifications. The Fashion District has finite space available, and storefronts are leased to premium brands and retailers. Brands or virtual landowners interested in partnering with Metaverse Group should contact mailto://info@metaversegroup.com.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in Web3 assets and businesses focused on the Metaverse, NFTs, DeFi, and gaming based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight-figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly-traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
About Forever 21
Forever 21 is a fashion industry leader making latest trends accessible to all while inspiring unique style and confidence. With a renewed focus on the customer experience, the brand offers high style designs and fashion basics with compelling values and a dynamic store environment. While driving innovation across e-commerce and digital to expand access and convenience, the brand continues to strengthen its positioning as today’s preferred destination for the fashionable consumer. Forever 21 is located in more than 540 locations globally and online. For more information visit https://Forever21.com.
Visit: https://forever21.com.
Follow @forever21 on Instagram, Facebook and Twitter.
About Authentic Brands Group
Authentic Brands Group (ABG) is a brand development, marketing and entertainment company, which owns a portfolio of global media, entertainment and lifestyle brands. Headquartered in New York City, ABG elevates and builds the long-term value of more than 50 consumer brands and properties by partnering with best-in-class manufacturers, wholesalers and retailers. Its brands have a global retail footprint across the luxury, specialty, department store, mid-tier, mass and e-commerce channels and in more than 7,500 freestanding stores and shop-in-shops around the world.
ABG is committed to transforming brands by delivering compelling product, content, business and immersive experiences. It creates and activates original marketing strategies to drive the success of its brands across all consumer touchpoints, platforms and emerging media. ABG’s portfolio of iconic and world-renowned brands includes Marilyn Monroe®, Elvis Presley®, Muhammad Ali®, Shaquille O'Neal®, David Beckham®, Dr. J®, Greg Norman®, Neil Lane®, Thalia®, Sports Illustrated®, Reebok®, Eddie Bauer®, Spyder®, Volcom®, Airwalk®, Nautica®, Izod®, Forever 21®, Aéropostale®, Juicy Couture®, Vince Camuto®, Lucky Brand®, Nine West®, Jones New York®, Frederick's of Hollywood®, Adrienne Vittadini®, Van Heusen®, Arrow®, Tretorn®, Tapout®, Prince®, Vision Street Wear®, Brooks Brothers®, Barneys New York®, Judith Leiber®, Herve Leger®, Frye®, Hickey Freeman®, Hart Schaffner Marx®, Thomasville®, Drexel® and Henredon®.
For more information, visit https://authenticbrands.com.
Follow ABG on Twitter, LinkedIn and Instagram.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005260/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email:mailto:// contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
Giana Elenterio, Director of Public Relations
mailto://gelenterio@authenticbrands.com
NEWS -- Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort
NEWS -- Provectus Biopharmaceuticals Announces Synthesis of New Halogenated Xanthene Small Molecule
KNOXVILLE, TN, March 24, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has successfully developed and manufactured a second halogenated xanthene (HX), adding to its lead, clinical-stage, HX small molecule called rose bengal sodium (RBS).
The molecular name of the newly synthesized HX is 4,5,6,7-tetrabromo-3',6'-dihydroxy-2',4',5',7'-tetraiodo-3H-spiro[isobenz- ofuran-1,9'-xanthen]-3-one.
Provectus’ intellectual property estate comprises an entire class of proprietary, related HX molecules that are proprietarily-synthesized using Quality-by-Design principles (QbD) under current Good Manufacturing Practice (cGMP) and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines.
Dominic Rodrigues, Vice Chair of the Company’s Board of Directors said, “Different permutations and combinations of halogen atoms on the backbone of this molecular class convey different biological, chemical, and/or physical properties to each class member. We are excited to have produced a new halogenated xanthene, further expanding our medical science platform. We look forward to developing this small molecule into a viable Provectus drug product candidate.”
About Provectus
Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a class of small molecules called halogenated xanthenes. Multi-route of administration drug discovery and development programs include investigational drugs and drug targets in oncology (clinical-stage), dermatology (clinical-stage), hematology, virology, microbiology, ophthalmology (clinical-stage), and animal health. Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, https://www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at https://www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the SEC, including those described in Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and Provectus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2021.
###
Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999
NEWS -- Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company
Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, announces the appointment of Greg Burel, former Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR) Director of the Strategic National Stockpile (SNS), to the Company’s Biothreat Advisory Board and as a senior advisor to the Company.
Mr. Burel served as the Director of SNS from March 2007 to January 2020. In this role, Mr. Burel directed the nation’s premier medical materiel preparedness and response organization charged with delivering critical medical assets to the site of a national emergency. In addition, his prior service includes senior management roles with increasing responsibility with the Federal Emergency Management Agency (FEMA) and the General Services Administration (GSA). Mr. Burel recently retired after nearly 38 years of federal service in January of 2020.
Mr. Burel stated, “I am excited to support and help advance Heat’s biodefense initiatives. The COVID pandemic has only reinforced the urgent need for a rapid, safe, and effective response to potential biological threats. Moreover, current geopolitical events highlight the need for an effective response to biological weapons. For this reason, it is essential to have effective therapies that can be stockpiled in advance, and then rapidly customized, manufactured, and deployed to address imminent and future threats.”
Jeff Wolf, Chief Executive Officer of Heat, commented, “We are honored to welcome Greg to our Biothreat Advisory Board, given his decades of experience preparing for and responding to public health threats, including pandemics, chemical and biological agents and more. In addition to his role with the advisory board, he will also serve as a senior advisor and consultant to the Company, where he will provide strategic advice, support outreach initiatives for our core biodefense programs. He will also support our anthrax initiative and the development and rollout of RapidVax®, our novel cellular vaccine designed for rapid “plug and play” programming and stockpiling against emerging known and unknown biological threats. We look forward to leveraging his deep expertise as we seek to grow our biodefense portfolio in the US and abroad.”
In addition to Mr. Burel, current members of the Biothreat Advisory Board include former US Senator Mark Pryor; David Lasseter, former Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction; former US Representative Jack Kingston, who also serves as the Secretariat of the Alliance for Biosecurity; Andrew C. Weber, former Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs; and Dr. Gregory Koblentz, Associate Professor at George Mason University and leading expert on chemical and biological weapons.
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies and vaccines to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in a Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
For more information, please visit: https://www.heatbio.com, and also follow us on Twitter.
Forward Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements regarding leveraging Mr. Burel’s deep expertise as Heat seeks to grow its biodefense portfolio in the US and abroad. These statements are subject to leverage Mr. Burel’s expertise and to grow its biodefense portfolio, Heat’s ability to successfully consummate the merger of Elusys, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities and its cash and short-term investments providing significant runway to fund Heat’s current clinical programs and further expand Heat’s therapeutic portfolio , its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K for the year ended December 31, 2021 filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://investorrelations@heatbio.com
NEWS -- Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results
Conference Call to be held Wednesday, March 23, 2022 at 5:00 pm (EST)
DUBLIN, Ohio, March 23, 2022--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the fourth quarter and year-to-date for the period ended December 31, 2021.
To view full source version on businesswire.com: https://www.businesswire.com/news/home/20220323005340/en/
NEWS -- Metaverse Fashion Week Announces Participating Brands and Musical Guests
TORONTO, March 23, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to share the names of participating brands in Decentraland’s Metaverse Fashion Week. The event will take place on digital real estate owned by Tokens.com’s subsidiary, Metaverse Group and will take place from March 24th to 27th.
The Luxury Fashion District, owned by Metaverse Group, will host fashion houses, brands, and designers. Several iconic brands will make their Web3 debut, including Dolce & Gabbana, Etro, Elie Saab, Imitation of Christ, Dundas, Nicholas Kirkwood, FaithTribe, Chufy, Monnier Frères, Franck Muller, Gary McQueen, and Guo Pei.
"Metaverse Fashion Week is the start of a new era in fashion that is accessible to everyone across the globe at the same time. The event is free to attend, and all that’s needed is a computer with internet access," commented Andrew Kiguel, CEO and Founder of Tokens.com and Executive Chairman of Metaverse Group. "Metaverse Fashion Week is a great way for brands to access a new demographic that would otherwise be difficult for them to reach."
Metaverse Fashion Week events will feature over 60 brands including GM (General Motors) showcasing their latest electric vehicles, Tommy Hilfiger, DKNY, DRESSX, Estée Lauder, Karl Lagerfeld, and Alexander McQueen.
Musical guests closing this historic event will be Grimes and Auroboros. The immersive DJ set and sonic lightshow will be held on the 27th of March at 10pm BST / 5pm EDT.
Decentraland’s vision for Metaverse Fashion Week is to provide a space for a new era in fashion, showing the world the power of decentralization and the developing Web3 ecosystem. The platform’s guiding philosophy is meant to build an alternate reality that democratizes access to all facets of our modern economy. By building in diversity, inclusion, and accessibility, Decentraland is creating the place for the next generation of commerce and adventure. For more information on Metaverse Fashion Week visit https://mvfw.org/.
Brands and businesses interested in partnering with Metaverse Group should contact mailto://info@metaversegroup.com.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns and invests in an inventory of Metaverse, NFT, DeFi, and gaming based digital assets. Tokens.com’s focus is to invest in and build Web3 businesses through its primary entity and subsidiaries. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly-traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
About Decentraland
Decentraland is a decentralized virtual social platform powered by the Ethereum blockchain. Within the Decentraland platform, users can create, experience, and monetize content and applications. Decentraland is unique in that it is owned and governed by the people who use the platform every day. Through the decentralized autonomous organization (DAO) users can submit proposals for owners of MANA (Decentraland currency) and LAND (Decentraland property) to vote on.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005245/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
+1-647-578-7490
mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
mailto://contact@tokens.com
Media: Ryleigh Ebron – Talk Shop Media
mailto://ryleigh@talkshopmedia.com
NEWS -- Metaverse Fashion Week Announces Participating Brands and Musical Guests
TORONTO, March 23, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to share the names of participating brands in Decentraland’s Metaverse Fashion Week. The event will take place on digital real estate owned by Tokens.com’s subsidiary, Metaverse Group and will take place from March 24th to 27th.
The Luxury Fashion District, owned by Metaverse Group, will host fashion houses, brands, and designers. Several iconic brands will make their Web3 debut, including Dolce & Gabbana, Etro, Elie Saab, Imitation of Christ, Dundas, Nicholas Kirkwood, FaithTribe, Chufy, Monnier Frères, Franck Muller, Gary McQueen, and Guo Pei.
"Metaverse Fashion Week is the start of a new era in fashion that is accessible to everyone across the globe at the same time. The event is free to attend, and all that’s needed is a computer with internet access," commented Andrew Kiguel, CEO and Founder of Tokens.com and Executive Chairman of Metaverse Group. "Metaverse Fashion Week is a great way for brands to access a new demographic that would otherwise be difficult for them to reach."
Metaverse Fashion Week events will feature over 60 brands including GM (General Motors) showcasing their latest electric vehicles, Tommy Hilfiger, DKNY, DRESSX, Estée Lauder, Karl Lagerfeld, and Alexander McQueen.
Musical guests closing this historic event will be Grimes and Auroboros. The immersive DJ set and sonic lightshow will be held on the 27th of March at 10pm BST / 5pm EDT.
Decentraland’s vision for Metaverse Fashion Week is to provide a space for a new era in fashion, showing the world the power of decentralization and the developing Web3 ecosystem. The platform’s guiding philosophy is meant to build an alternate reality that democratizes access to all facets of our modern economy. By building in diversity, inclusion, and accessibility, Decentraland is creating the place for the next generation of commerce and adventure. For more information on Metaverse Fashion Week visit https://mvfw.org/.
Brands and businesses interested in partnering with Metaverse Group should contact mailto://info@metaversegroup.com.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns and invests in an inventory of Metaverse, NFT, DeFi, and gaming based digital assets. Tokens.com’s focus is to invest in and build Web3 businesses through its primary entity and subsidiaries. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly-traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
About Decentraland
Decentraland is a decentralized virtual social platform powered by the Ethereum blockchain. Within the Decentraland platform, users can create, experience, and monetize content and applications. Decentraland is unique in that it is owned and governed by the people who use the platform every day. Through the decentralized autonomous organization (DAO) users can submit proposals for owners of MANA (Decentraland currency) and LAND (Decentraland property) to vote on.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005245/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
+1-647-578-7490
mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
mailto://contact@tokens.com
Media: Ryleigh Ebron – Talk Shop Media
mailto://ryleigh@talkshopmedia.com
NEWS -- Plus Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest.
The conference will take place March 28-30, 2022, with pre-recorded presentations available on-demand through the conference portal at 2022 Virtual Growth Conference and available under the For Investors tab of the Plus website at https://www.plustherapeutics.com. This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member here: Reserve Your Seat.
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company focused on developing innovative, targeted radiotherapeutics for adults and children worldwide with rare and difficult-to-treat cancers. Our proprietary radiotherapeutic platform uniquely uses nanoliposomes to encapsulate and deliver the radioisotope, Rhenium, into or near a tumor via a single, direct infusion. The lead radiotherapeutic in our pipeline, Rhenium-186 NanoLiposome (186RNL), is being evaluated in U.S. multi-center clinical trials for the treatment of recurrent glioblastoma and leptomeningeal metastases. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-LM or the ReSPECT-PBC trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations via a seventh patient cohort; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
Westwicke/ICR
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
Westwicke/ICR
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
NEWS -- Nanomix to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
EMERYVILLE, Calif., March 22, 2022--(BUSINESS WIRE)--Nanomix Corporation (OTCBB: NNMX, NNMXD), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that David Ludvigson, President and Chief Executive Officer, will participate in the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, being held virtually March 28-30, 2022.
A pre-recorded company presentation will be available to conference attendees for 72 hours beginning March 28 at 9:00 a.m. Eastern time and can be accessed here. An archived replay of the webcast will also be available on Nanomix’s investor relations website. Interested investors may register for the conference to access the webcast at https://m-vest.com/events/2022-virtual-growth-conference.
During this virtual conference, investors will hear from executives from a wide range of sectors including Biotech, Clean Energy, Electric Vehicles, Financial Services, Fintech & REITS, Gaming & Entertainment, Healthcare, Healthcare IT, Infrastructure, Shipping and Technology/ Media/Telecom. The conference will feature company presentations, fireside chats, roundtable discussions and live Q&A with CEOs moderated by Maxim Research Analysts.
About Nanomix Corporation
Nanomix is the leader in the development of mobile point-of-care diagnostics with its Nanomix eLab platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, with the goal to enable faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assay addresses the critical need for faster diagnosis of critical infections. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes. For more information, visit https://www.nano.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322005470/en/
Contacts
LHA Investor Relations
Tirth T. Patel
212-201-6614
mailto://tpatel@lhai.com
NEWS -- Plus Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases
ReSPECT-LM trial to evaluate safety/tolerability and identify MTD/MFD in three cohorts
Rhenium-186 NanoLiposome (186RNL) now in two active U.S. clinical trials for CNS cancers
AUSTIN, Texas, March 22, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the first patient has been dosed in the ReSPECT-LM Phase 1/2a dose escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of patients with leptomeningeal metastases (LM).
The investigational drug, 186RNL, is a proprietary nanoscale compound with a unique chelated radioisotope that is administered locally as a single dose via a conventional Ommaya reservoir. Rhenium-186 is a dual energy emitter (beta and gamma) with a short average path length for high precision, low dose rate that is safer for normal tissues, and high radiation density that overwhelms innate DNA repair mechanisms. The dual energy emission allows real time evaluation and monitoring of the 186RNL administration.
The disease target, solid tumor-originating LM, is a deadly and increasingly common central nervous system (CNS) complication potentially from all solid cancer, with breast cancer, lung cancer, gastrointestinal cancer and melanoma being the most common primary sources of LM, with 110,000 cases diagnosed annually in the U.S. LM affects the membranes (meninges) surrounding the brain and spinal cord. There are currently no meaningfully effective Food and Drug Administration-approved treatments.
“The rationale for use of 186RNL in LM patients is scientifically quite attractive, and in clinical practice was very straightforward to administer to our first patient,” said Michael Youssef, M.D., Assistant Professor of Neuro-Oncology at University of Texas Southwestern and site Principal Investigator. “Quality of life and survival rates are poor among patients diagnosed with LM from solid tumors. With no standard of care, this represents a true unmet medical need in neuro-oncology.”
“LM affects about 10 times the number of patients as glioblastoma but carries a substantially worse prognosis,” said Norman LaFrance, M.D., Chief Medical Officer and SVP of Plus Therapeutics. “Initiating treatment in LM patients with 186RNL marks an important milestone for Plus Therapeutics and potentially for the LM patient population.”
The ReSPECT-LM trial (NCT05034497) is a multicenter, sequential cohort, open-label, single dose, dose escalation Phase 1/2a study using a modified Fibonacci 3+3 study design. It will evaluate the maximum tolerated dose (MTD), maximum feasible dose (MFD), safety and efficacy of a single administration of 186RNL via intraventricular catheter for LM following standard surgical, radiation and/or chemotherapy treatment. The primary endpoints of the study are the incidence and severity of adverse events/serious adverse events and dose limiting toxicities. Secondary endpoints include overall response rate, duration of response, progression free survival and overall survival.
The ReSPECT-LM Phase 1/2a clinical trial follows preclinical studies in which tolerance to doses of 186RNL as high as 1,075 Gy was shown in animal models with LM with no observed significant toxicity. Treatment led to marked reduction in tumor burden in two animal models of LM.
The Company recently announced the FDA granted Fast Track designation to 186RNL for the treatment of LM. Fast Track designation confers several benefits to the drug development program including 1) more frequent meetings with and written communication from FDA, 2) eligibility for Accelerated Approval and Priority Review, if relevant criteria are met, and 3) Rolling Review, which allows a drug company to submit completed sections of its New Drug Application (NDA) for review by FDA, rather than wait until every section of the NDA is completed before the entire application can be reviewed.
About Leptomeningeal Metastases (LM)
LM is a rare complication of cancer in which the disease spreads to the membranes (meninges) surrounding the brain and spinal cord. LM occurs in approximately 5% of people with cancer and is usually terminal with one-year and two-year survival of just 7% and 3% respectively. LM can originate from solid tumors, primary brain tumors, or hematological malignancies.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases.
Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-LM or the ReSPECT-PBC trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations via a seventh patient cohort; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
NEWS -- Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss
NEWS -- Tokens.com to Announce Its Audited Financial Results for Year Ended December 31, 2021 on March 31st, 2022
TORONTO, Ontario, March 21, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to share that it will announce its audited financial results for the year ended December 31, 2021 on March 31st.
An investor call hosted by CEO Andrew Kiguel has been scheduled to discuss the Company’s 2021 financial results starting at 10:00 am ET on Friday April 1st, 2022.
Date: April 1, 2022 Time: 10:00 a.m. ET
Dial-In: (866)455-3403 PIN: 57798376#
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns and invests in an inventory of Metaverse, NFT, DeFi, and gaming based digital assets. Tokens.com’s focus is to invest in and build Web3 businesses through its primary entity and subsidiaries. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005160/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com to Announce Its Audited Financial Results for Year Ended December 31, 2021 on March 31st, 2022
TORONTO, Ontario, March 21, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to share that it will announce its audited financial results for the year ended December 31, 2021 on March 31st.
An investor call hosted by CEO Andrew Kiguel has been scheduled to discuss the Company’s 2021 financial results starting at 10:00 am ET on Friday April 1st, 2022.
Date: April 1, 2022 Time: 10:00 a.m. ET
Dial-In: (866)455-3403 PIN: 57798376#
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns and invests in an inventory of Metaverse, NFT, DeFi, and gaming based digital assets. Tokens.com’s focus is to invest in and build Web3 businesses through its primary entity and subsidiaries. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005160/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
If I go to any of the message boards that I follow, read any message there, and then scroll down to see the price quote data, they all say that the volume for the day is exactly 1,234 shares! What is going on? Did anyone else point this out?
NEWS -- Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity
New insights into pelareorep's immune-related mechanism of action demonstrate it stimulates an innate immune response that in turn triggers adaptive anti-tumor immunity
Specificity for tumor cells compared to normal cells likely results from the impairment of viral detection/interferon responses in malignant cells
SAN DIEGO and CALGARY, AB, March 17, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical and patient data on pelareorep in the peer-reviewed journal Immunology. The paper, entitled "Oncolytic virus treatment differentially affects the CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity," was published in collaboration with researchers at several prestigious institutions, including the University of Leeds School of Medicine and the Institute of Cancer Research, London. A link to the paper can be found by clicking here (https://onlinelibrary.wiley.com/doi/10.1111/imm.13453).
Described in the paper are in vitro studies evaluating pelareorep's effects on Natural Killer (NK) cells as well as analyses of blood samples from patients with colorectal liver metastases taken prior to and after treatment with pelareorep. Results showed pelareorep treatment led to the activation of NK cells, which are known to directly kill cancer cells while stimulating adaptive anti-tumor immunity. The beneficial effects of pelareorep were observed both in patient samples and in vitro and were mediated by type 1 interferon (IFN-1) signaling, a key pathway involved in immunoregulation and tumor cell recognition.
"These important results further demonstrate both pelareorep's innate and adaptive immunologic mechanism of action, and we are pleased to have them published in such a prestigious, peer-reviewed journal," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech and co-author of the paper. "When viewing these findings, alongside prior clinical data demonstrating pelareorep's ability to activate T cells while promoting their infiltration into tumors, we see pelareorep delivering a robust, coordinated anti-cancer immune response driven by both the innate and adaptive immune systems. Looking forward, we will continue to leverage the immunotherapeutic effects of pelareorep as we further its development as an enabling technology for a wide cross-section of immunotherapeutic agents in breast cancer and other oncologic indications with high unmet needs."
Patient samples evaluated in the publication were from a completed window-of-opportunity clinical study evaluating pelareorep in colorectal cancer patients with liver metastases. Patients received between one and five doses of pelareorep prior to planned surgery to resect metastases. Blood samples were taken both prior to and at multiple time points after pelareorep treatment. Additional details of the trial, as well as previously reported results, are available in prior peer-reviewed publications1,2.
References:
1. Adair RA, Roulstone V, Scott KJ, et al. Sci Transl Med. 2012;4(138):138ra77. doi:10.1126/scitranslmed.3003578
2. El-Sherbiny YM, Holmes TD, Wetherill LF, et al. Clin Exp Immunol. 2015;180(1):98-107. doi:10.1111/cei.12562
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: https://www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' plans to advance towards a registration study in metastatic breast cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Company Contact
Jon Patton
Director of IR & Communication
+1-858-886-7813
mailto://jpatton@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
mailto://tim@lifesciadvisors.com
View original content: https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-publication-of-preclinical-and-patient-data-demonstrating-pelareoreps-stimulation-of-natural-killer-cell-anti-cancer-activity-301504761.html
SOURCE Oncolytics Biotech® Inc.
View original content: http://www.newswire.ca/en/releases/archive/March2022/17/c5251.html
If I go to any of the message boards that I follow, read any message there, and then scroll down to see the price quote data, they all say that the volume for the day is exactly 1,234 shares! What is going on? Did anyone else point this out?
NEWS -- Provectus Biopharmaceuticals Announces Oral Presentation of Updated Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference
KNOXVILLE, TN, March 16, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of neuroendocrine tumors (NET) metastatic to the liver (mNET) refractory to somatostatin analogs (SSAs) and peptide receptor radionuclide therapy (PRRT) (NCT02693067) was presented at the annual conference of the European Neuroendocrine Tumor Society (ENETS), held from March 10-11, 2022 in a hybrid setting in Barcelona, Spain and online.
The oral presentation was made by the principal investigator of the clinical trial’s single center at The Queen Elizabeth Hospital (TQEH) in Adelaide, Australia: Tim Price, MBBS, DHlthSc (Medicine), FRACP, Head of Clinical Oncology Research and Chair of the combined Hematology and Medical Oncology Unit at TQEH, and Clinical Professor in the Faculty of Medicine at the University of Adelaide.
Highlights from the 2022 ENETS Presentation:
NEWS -- Navidea Biopharmaceuticals to Host Fourth Quarter 2021 Earnings Conference Call and Business Update
Conference Call to be Held on Wednesday, March 23, 2022 at 5:00 p.m. (EDT)
DUBLIN, Ohio, March 16, 2022--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, March 23, 2022 at 5:00 p.m. (EDT) to discuss corporate developments and financial results for the fourth quarter ended December 31, 2021.
Dr. Michael Rosol, Chief Medical Officer, and Erika Eves, Vice President of Finance and Administration, will host the call and webcast to discuss the financial results and provide an update on recent developments and clinical progress. Management will be available to answer questions live immediately following the earnings announcement and prepared remarks portion of the call.
To participate in the call and webcast, please refer to the information below:
Event: Fourth Quarter 2021 Earnings Conference Call and Business Update
Date: Wednesday, March 23, 2022
Time: 5:00 p.m. (EDT)
U.S. & Canada Dial-In: 877-407-0312
International Dial-In: +1 201-389-0899
Conference ID: 13726541
Webcast Link: https://www.webcast-eqs.com/navidbioph20220323/en
A live audio webcast of the conference call will also be available on the investor relations page of Navidea’s corporate website at https://www.navidea.com. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navidea’s website.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit https://www.navidea.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at https://www.sec.gov or at http://ir.navidea.com.
Investors are urged to consider statements that include the words "will," "may," "could," "should," "plan," "continue," "designed," "goal," "forecast," "future," "believe," "intend," "expect," "anticipate," "estimate," "project," and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005218/en/
Contacts
Investor Relations Contact
Navidea Biopharmaceuticals, Inc.
Jeffrey Smith
Vice President of Operations
614-822-2365
mailto://jsmith@navidea.com
NEWS -- Tokens.com Partners with Meta Yachts to Create Virtual Yachts and Marina in the Metaverse
TORONTO, March 16, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to share that its subsidiary, Metaverse Group (https://metaversegroup.com/), has successfully entered a joint venture with Meta Yachts (https://metayachts.club/) to build a first of its kind luxury virtual marina, and eight unique superyacht NFTs, in Decentraland.
The initial development will be built on 25 parcels of Metaverse Group’s virtual land, with the marina’s launch happening in time for Metaverse Fashion Week, which takes place from March 24th to 27th. The eight superyachts will each have a private berth in the Meta Marina, offering owners and guests an immersive experience that features a breakwater, an animated ocean, and ambient noise (seagulls, boat horns, etc.). The fashion yacht is designed to house virtual meeting rooms, catwalks, and even a space to display and sell digital wearables.
"The partnership with Meta Yachts expands our revenue streams through the sale of NFTs and the advertising potential as the marina is a Metaverse landmark, bringing in more visitor traffic. The yachts will provide guests with immersive luxury experiences. This opens up new innovative advertising opportunities in the Metaverse," commented Andrew Kiguel, CEO of Tokens.com and Executive Chairman of Metaverse Group.
As the possibilities of the interior functionalities of each yacht are essentially limitless, luxury brands will have the freedom to create any virtual world experience they like once onboard. The team is already designing several yacht concepts for various luxury brands. Meta Yachts will also feature as a sponsor at NFT MENA (https://nftmenaexhibit.com/), where the company will have a hologram on display throughout the event.
"Metaverse Group are early pioneers of virtual real estate, including owning a massive 166 parcel estate in Decentraland’s Fashion District. The company comprises a rock-solid dream team with extensive experience across finance, digital assets, non-fungible tokens, blockchain technology and yachting, which is the perfect complement to our skillset," said Meta Yachts co-founder Thomas O’Nial.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in Web3 assets and businesses focused on the Metaverse, NFTs, DeFi, and gaming based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight-figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly-traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
Brands or virtual landowners interested in partnering with Metaverse Group should contact mailto://info@metaversegroup.com.
About Meta Yachts
Meta Yachts is the premier superyacht provider in the Metaverse. The company has designed and built eight unique, fully-functional 3D superyachts, each showcasing a distinct concept. They’ve built the Meta Marina to go with it; the world’s very first metaverse marina which will also serve as the headquarters of the company. Meta Yachts will launch in Decentraland before the inaugural virtual Fashion Week, which starts on 24th March, 2022.
For further information, please visit https://www.metayachts.club
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005226/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com Partners with Meta Yachts to Create Virtual Yachts and Marina in the Metaverse
TORONTO, March 16, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to share that its subsidiary, Metaverse Group (https://metaversegroup.com/), has successfully entered a joint venture with Meta Yachts (https://metayachts.club/) to build a first of its kind luxury virtual marina, and eight unique superyacht NFTs, in Decentraland.
The initial development will be built on 25 parcels of Metaverse Group’s virtual land, with the marina’s launch happening in time for Metaverse Fashion Week, which takes place from March 24th to 27th. The eight superyachts will each have a private berth in the Meta Marina, offering owners and guests an immersive experience that features a breakwater, an animated ocean, and ambient noise (seagulls, boat horns, etc.). The fashion yacht is designed to house virtual meeting rooms, catwalks, and even a space to display and sell digital wearables.
"The partnership with Meta Yachts expands our revenue streams through the sale of NFTs and the advertising potential as the marina is a Metaverse landmark, bringing in more visitor traffic. The yachts will provide guests with immersive luxury experiences. This opens up new innovative advertising opportunities in the Metaverse," commented Andrew Kiguel, CEO of Tokens.com and Executive Chairman of Metaverse Group.
As the possibilities of the interior functionalities of each yacht are essentially limitless, luxury brands will have the freedom to create any virtual world experience they like once onboard. The team is already designing several yacht concepts for various luxury brands. Meta Yachts will also feature as a sponsor at NFT MENA (https://nftmenaexhibit.com/), where the company will have a hologram on display throughout the event.
"Metaverse Group are early pioneers of virtual real estate, including owning a massive 166 parcel estate in Decentraland’s Fashion District. The company comprises a rock-solid dream team with extensive experience across finance, digital assets, non-fungible tokens, blockchain technology and yachting, which is the perfect complement to our skillset," said Meta Yachts co-founder Thomas O’Nial.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in Web3 assets and businesses focused on the Metaverse, NFTs, DeFi, and gaming based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight-figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly-traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
Brands or virtual landowners interested in partnering with Metaverse Group should contact mailto://info@metaversegroup.com.
About Meta Yachts
Meta Yachts is the premier superyacht provider in the Metaverse. The company has designed and built eight unique, fully-functional 3D superyachts, each showcasing a distinct concept. They’ve built the Meta Marina to go with it; the world’s very first metaverse marina which will also serve as the headquarters of the company. Meta Yachts will launch in Decentraland before the inaugural virtual Fashion Week, which starts on 24th March, 2022.
For further information, please visit https://www.metayachts.club
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005226/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com Announces Listing of Warrants on the NEO Exchange
Not for distribution to United States newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States.
TORONTO, March 15, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to announce that the NEO Exchange (the "NEO") has accepted for listing 8,888,948 common share purchase warrants of the Company (the "Warrants") for trading on the NEO, which were issued in connection with a private placement offering of units by the Company that closed on November 16, 2021 (the "Offering"). Up to an additional 506,668 warrants may be listed at a future date subject to exercise of certain broker warrants issued in connection with the Offering. For more information about the Offering, please refer to the Company’s news release dated November 16, 2021, which is available under the Company’s SEDAR profile at https://www.sedar.com.
Each Warrant entitles the holder thereof to purchase one common share in the capital of the Company at a price of $1.15 per common share until November 16, 2024. The Warrants are governed by the terms of a warrant indenture dated November 16, 2021 (the "Warrant Indenture") between the Company and Computershare Trust Company of Canada as warrant agent, a copy of which is available under the Company’s SEDAR profile at https://www.sedar.com. Subsequent to the closing of the Offering, the warrant agent was changed from Computershare to Odyssey Trust Company. For further details regarding the Warrants, please refer to the Warrant Indenture.
The Warrants are expected to commence trading on the NEO at the open of markets on March 17, 2022 under the trading symbol "COIN.WT".
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns and invests in an inventory of Metaverse, NFT, DeFi, and gaming based digital assets. Tokens.com’s focus is to invest in and build Web3 businesses through its primary entity and subsidiaries. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005286/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com Announces Listing of Warrants on the NEO Exchange
Not for distribution to United States newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States.
TORONTO, March 15, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to announce that the NEO Exchange (the "NEO") has accepted for listing 8,888,948 common share purchase warrants of the Company (the "Warrants") for trading on the NEO, which were issued in connection with a private placement offering of units by the Company that closed on November 16, 2021 (the "Offering"). Up to an additional 506,668 warrants may be listed at a future date subject to exercise of certain broker warrants issued in connection with the Offering. For more information about the Offering, please refer to the Company’s news release dated November 16, 2021, which is available under the Company’s SEDAR profile at https://www.sedar.com.
Each Warrant entitles the holder thereof to purchase one common share in the capital of the Company at a price of $1.15 per common share until November 16, 2024. The Warrants are governed by the terms of a warrant indenture dated November 16, 2021 (the "Warrant Indenture") between the Company and Computershare Trust Company of Canada as warrant agent, a copy of which is available under the Company’s SEDAR profile at https://www.sedar.com. Subsequent to the closing of the Offering, the warrant agent was changed from Computershare to Odyssey Trust Company. For further details regarding the Warrants, please refer to the Warrant Indenture.
The Warrants are expected to commence trading on the NEO at the open of markets on March 17, 2022 under the trading symbol "COIN.WT".
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns and invests in an inventory of Metaverse, NFT, DeFi, and gaming based digital assets. Tokens.com’s focus is to invest in and build Web3 businesses through its primary entity and subsidiaries. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005286/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Heat Biologics Provides Year-End 2021 Business Update
DURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the year ended December 31, 2021.
Jeff Wolf, Chief Executive Officer of Heat, commented, “2021 was a transformative year for Heat as we progress our strategic evolution to become a fully-integrated biopharmaceutical company. On the clinical front, we presented favorable survival data at The American Association of Cancer Research (AACR) of HS-110 in combination with checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC). We recently submitted meeting requests to the FDA for separate Type B (“End of Phase 2 Meeting”) and Type C (Phase 3 “CMC Readiness Meeting”) meetings to receive feedback on our proposed trial design and regulatory path forward. We anticipate these meetings will be scheduled for the second quarter of 2022. Following these meetings, we should be in a better position to advance potential strategic discussions regarding this program.”
“In September, based on our positive review of the Phase 1 data generated to date, we announced additional dose levels for our Phase 1 clinical trial evaluating the safety of PTX-35 monotherapy in patients with solid tumors and look forward to reporting the results of this trial later this year. We also recently announced new data demonstrating a single dose of the preclinical version of PTX-35 (mPTX-35), was able to expand regulatory T cells (Tregs) and significantly improve disease and graft survival outcome in a model of pancreatic islet allotransplantation for the treatment of diabetes.”
“We continued to make great strides towards becoming a fully integrated biotech capable of driving innovations from discovery through delivery. With the formation of Skunkworx Bio, we have ramped up our in-house discovery of biologics for our preclinical and clinical development efforts.”
“Our biomanufacturing and analytical team at Scorpion Biological Services broke ground on a new facility in San Antonio, Texas, designed to decrease our dependence on third-party CDMOs, reducing costs and accelerating timelines. In addition to supporting our own internal operations, we intend to offer manufacturing services to other biopharma companies on a fee-for-service basis. These efforts reinforce our goal of maximizing efficiency of drug development to expedite the delivery of novel immune activating therapies.”
“At the World Vaccine Conference, we announced our new biosecurity/biodefense initiative led by RapidVax®, a novel vaccine platform designed to enable an accelerated response and long-lasting immunological memory against a wide variety of infectious agents. RapidVax is designed to utilize a common unprogrammed vaccine base that can be manufactured in bulk, stockpiled, and rapidly customized upon identification of a biological threat to enable an accelerated time to clinic that can harness shared development, clinical safety, and manufacturing synergies. Our gp96-based cellular vaccines have previously demonstrated prophylactic protection in animal models against a range of diseases, including malaria, HIV/SIV, Zika and SARS-CoV-2 in multiple DOD and NIH-funded studies. Since launching this program, we have filed patents to protect our proprietary technology and have established our new Biothreat Advisory Board, which includes highly renowned individuals in the fields of biosecurity and biodefense, to guide the development of our programs.”
“In addition to our internal biodefense initiatives, we announced a definitive merger agreement to acquire Elusys Therapeutics, a commercial-stage biodefense company and the manufacturer of ANTHIM® (obiltoxaximab), which is approved for the treatment of inhalation anthrax in the U.S., Canada, Europe. Since announcing this acquisition, Elusys completed the first phase of a contract for $50 million with an option to procure up to an additional $31 million of ANTHIM by the first half of 2023. Given the growing global uncertainty, we believe the risks of anthrax and other biological threats are more present than ever. This acquisition is aligned with our strategy to take a leading role in the biodefense market.”
2021 Financial Results
NEWS -- RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS
CARLSBAD, Calif., March 14, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that full results from a Phase 1/2a clinical study of RG6501 (OpRegen®), a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be presented at the 2022 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2022) (https://www.arvo.org/annual-meeting/), to be held May 1 – 4, 2022 at the Colorado Convention Center in Denver, CO. The presentation, "Safety and Efficacy of a Phase 1/2a Clinical Trial of Transplanted Allogeneic Retinal Pigmented Epithelium (RPE, OpRegen) Cells in Advanced Dry Age-Related Macular Degeneration (AMD)" will be featured as part of the Retinal Prostheses and Transplantation Session, on May 2, 2022 between 3:00 PM to 5:00 PM MDT, by Allen C. Ho, M.D., FACS, Wills Eye Hospital Attending Surgeon and Director of Retina Research, Professor of Ophthalmology, Thomas Jefferson University, Mid Atlantic Retina and President, The Retina Society (abstract number 3714956). RG6501 (OpRegen) is currently being developed under an exclusive worldwide collaboration between Lineage, Roche and Genentech, a member of the Roche Group.
The Association for Research in Vision and Ophthalmology, Inc. (ARVO) was founded in 1928 in Washington, DC, by a group of 73 ophthalmologists. ARVO is the largest and most respected eye and vision research organization in the world. ARVO members include nearly 11,000 researchers from over 75 countries. ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders. For more information, please visit https://www.arvo.org/ or follow the association on Twitter @ARVOInfo.
About OpRegen
OpRegen® is a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, being developed under a worldwide collaboration between Lineage, Roche and Genentech, a member of the Roche Group. The Phase 1/2a open-label, dose escalation safety and efficacy study evaluated a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA and enrolled 24 patients into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with a best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort enrolled 12 better vision patients (BCVA from 20/65 to 20/250 with smaller mean areas of GA). Cohort 4 also included patients treated with a new "thaw-and-inject" formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. The primary objective of the study was to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. OpRegen has been well tolerated to date and there have been no new, unexpected ocular or systemic adverse events or serious adverse events related to OpRegen or study procedures that have not been previously reported.
About Dry AMD
Dry age-related macular degeneration (AMD) is a leading cause of adult blindness in the developed world. There are two forms of AMD: wet AMD and dry AMD. Dry AMD is the more common of the two types, accounting for approximately 85-90% of cases. Wet AMD is the less common of the two types, accounting for approximately 10-15% of cases. Global sales of the two leading wet AMD therapies were in excess of $10 billion in 2019. Nearly all cases of wet AMD begin as dry AMD. Dry AMD typically affects both eyes. There are currently no U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) approved treatment options available for patients with dry AMD.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic ("off-the-shelf") product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit https://www.lineagecell.com or follow the Company on Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005160/en/
Contacts
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
mailto://ir@lineagecell.com
(442) 287-8963
Solebury Trout IR
Mike Biega
mailto://Mbiega@soleburytrout.com
(617) 221-9660
Russo Partners – Media Relations
Nic Johnson or David Schull
mailto://Nic.johnson@russopartnersllc.com
mailto://David.schull@russopartnersllc.com
(212) 845-4242
NEWS -- Tokens.com Expands Virtual Real Estate Portfolio With Acquisition in NFT World Metaverse
TORONTO, March 14, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to share that its subsidiary, Metaverse Group, has purchased virtual NFT real estate in the NFT Worlds Metaverse.
NFT Worlds is a fully decentralized, fully customizable, community driven, play to earn gaming platform where world owners can create their own limitless Metaverse games or experiences for players or exclusive communities within their worlds.
Currently using Minecraft and its sprawling open-source ecosystem, NFT Worlds builds on the backbone of decades worth of open source development within the Minecraft community and radically expands on it to enable entirely new types of 3D voxel-based, decentralized gaming Metaverses backed by the Ethereum blockchain.
Metaverse Group’s purchase expands and diversifies its eight-figure real estate portfolio. NFT World parcels are staking compatible which introduces a new revenue stream to Metaverse Group. This parcel brings new opportunities for Metaverse Group, its partners and parties interested in establishing a presence in the Metaverse. Each NFT World is an explorable, limitless world that can be developed into anything you can imagine. NFT World is unique as it is compatible with Minecraft, in addition to being massively multiplayer, and decentralized.
"Adding this parcel to our portfolio diversifies our offering across 7 different Metaverses," commented Andrew Kiguel, CEO of Tokens.com and Executive Chairman of Metaverse Group. "We understand the popularity of Minecraft and are pleased to own a parcel compatible with it."
Brands or virtual landowners interested in partnering with Metaverse Group should contact mailto://Info@metaversegroup.com.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, P2E, DeFi, and NFT based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s CryptoValley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
About NFT World
NFT Worlds is a fully decentralized, fully customizable, community driven, play to earn gaming platform where world owners can create their own limitless Metaverse games or experiences for players or exclusive communities within their worlds.
Currently using Minecraft and it's sprawling open-source ecosystem, NFT Worlds builds on the backbone of decades worth of open source development within the Minecraft community and radically expands on it to enable entirely new types of 3D voxel-based, decentralized gaming Metaverses backed by the Ethereum blockchain.
For further information visit: https://www.nftworlds.com/
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005101/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
+1-647-578-7490
mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
mailto://contact@tokens.com
Media: Ryleigh Ebron – Talk Shop Media
mailto://ryleigh@talkshopmedia.com